SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

Nebius Group NV is a technology company that provides infrastructure and services to AI builders worldwide. It offers Nebius AI, an AI-centric cloud platform provides full-stack infrastructure, including large-scale GPU clusters, cloud services, and developer tools. The company also operates through specialized brands: Toloka AI, which partners in data for generative AI development; TripleTen, an edtech platform focused on re-skilling individuals for tech careers; and Avride, which develops autonomous driving technology. Nebius Group was founded by Elena Kolmanovskaya, Ilya Segalovich, Mikhail Fadeev, and Arkady Volozh in 1989 and is headquartered in Amsterdam, the Netherlands.

Nebius Group N.V. - Ordinary Shares - Class A

Nebius Group N.V. 

Nebius is being swept up in a broad selloff in AI infrastructure and neocloud stocks as traders question the sectors debt burden, financing costs, and long-term business sustainability. The community is split between buyers arguing NBIS has a stronger balance sheet than some peers and that the selloff is overdone, and bears expecting further valuation pressure.

What is Amp?  Amp is described as the new digital collateral token offering instant, verifiable assurances for any kind of value transfer. Using Amp, networks like Flexa can quickly and irreversibly secure transactions for a wide variety of asset-related use cases.  How does Amp work?  Amp claims to offer a straightforward but versatile interface for verifiable collateralization through a system of collateral partitions and collateral managers. Where collateral partitions can be designated to collateralize any account, application, or even transaction, and carry balances which are directly verifiable on the Ethereum blockchain, collateral managers are smart contracts that can lock, release, and redirect collateral in these partitions as needed in order to support value transfer activities. Amp supports a wide variety of use cases for collateralization, and also introduces the concept of predefined partition strategies, which can enable special capabilities such as collateral models through which tokens can be staked without ever leaving their original address.

AMP Token

AMP is drawing attention after a sharp price and volume surge, prompting bullish calls for a breakout alongside skepticism that it may be another short-lived pump. Traders speculate about Flexa/Anvil and crypto-payment themes, but the discussion does not establish a confirmed catalyst.

MARA Holdings, Inc. is a digital asset technology company, which engages in mining cryptocurrencies with a focus on the Bitcoin ecosystem. It also deals with owning and operating bitcoin mining facilities or data centers, selling proprietary software or technology to third parties operating in the Bitcoin ecosystem, offering advisory and consulting services to support Bitcoin mining ventures in domestic and international jurisdictions, and generating electricity from renewable energy resources or methane gas capture to power Bitcoin mining projects. The company was founded on February 23, 2010 and is headquartered in Hallandale Beach, FL.

MARA Holdings Inc.

Marathon Digital Holdings Inc

MARAs sharp extended selloff, including a break below support despite Bitcoin holding relatively firm, is driving discussion. Traders fault weak performance and uncertainty around the AI/data-center pivot and unsigned tenant deals, while some see oversold conditions and options positioning as grounds for a rebound.

Invesco QQQ Trust Series 1 - Invesco QQQ Trust Series 1

A sharp tech-led selloff, amid concerns about AI valuations and spending, has focused attention on QQQ; traders are debating whether the rebound is durable or a bull trap, with major tech earnings adding uncertainty.

AeroVironment, Inc. is a defense technology company delivering integrated capabilities across air, land, sea, space, and cyber. The company develops and deploys autonomous systems, loitering munitions, counter-UAS technologies, space-based platforms, directed energy systems, and cyber and electronic warfare capabilities-built to meet the mission needs of today’s warfighter and tomorrow’s conflicts. At the core of these technologies lies AV_Halo, a modular, mission-ready suite of AI-powered software tools that empowers warfighters and enables full-battlefield dominance: detect, decide, deliver. With a national manufacturing footprint and a deep innovation pipeline, AV delivers proven systems and future-defining capabilities at speed, scale, and operational relevance. The company was founded by Paul B. MacCready, Jr. in July 1971 and is headquartered in Arlington, VA.

AeroVironment Inc.

AeroVironments sharp decline alongside other drone and defense stocks is driving attention, with traders debating whether weak sector sentiment, valuation concerns and budget uncertainty outweigh strong contract activity and demand for its drone and counter-drone systems. Bulls also point to a recent earnings beat and record funded backlog, while skeptics question execution, cash flow and the lack of a raised full-year outlook.

Bloom Energy Corp. engages in the manufacture and installation of a solid oxide fuel-cell based power generation platform. Its product, Bloom Energy Server, converts standard low-pressure natural gas or biogas into electricity through an electrochemical process without combustion. The company was founded by K. R. Sridhar, John Finn, Jim McElroy, Matthias Gottmann, and Dien Nguyen on January 18, 2001, and is headquartered in San Jose, CA.

Bloom Energy Corp - Ordinary Shares - Class A

Bloom Energy is drawing attention for sharp swings amid a broader AI-stock selloff, with traders pointing to rate and inflation worries and concerns about AI spending after OpenAI revenue reports. Bulls see the weakness as a buying opportunity ahead of Q3 earnings, citing data-center power demand and Blooms fuel-cell deals, while bears question the stocks valuation and near-term momentum.

Strategy, Inc. engages in the development of fixed-income instruments that provide investors varying degrees of economic exposure to bitcoin. It executes bitcoin acquisition, capital management, and capital markets strategies. The company was founded by Michael J. Saylor and Sanjeev K. Bansal on November 17, 1989, and is headquartered in Tysons Corner, VA.

Strategy Inc. - Ordinary Shares - Class A

Strategy

Strategy shares are under pressure amid MSCI rules that could lead to removal from its indexes and trigger passive-fund selling; the removal is not confirmed. Traders debate whether the risk is already priced in, while also weighing Bitcoin weakness and MSTRs sensitivity to BTC against dip-buying hopes.

Amazon.com, Inc. is a multinational technology company, which engages in the provision of online retail shopping services. It operates through the following segments: North America, International, and Amazon Web Services (AWS). The North America segment offers retail sale of consumer products, including from sellers, advertising, and subscriptions services through North America-focused online and physical stores. The International segment focuses on retail sale of consumer products, including sellers, advertising, and subscription services through internationally focused online stores. The AWS segment is composed of global sales of computers, storage, databases, and other services for start-ups, enterprises, government agencies, and academic institutions. The company was founded by Jeffrey P. Bezos in July 1994 and is headquartered in Seattle, WA.

Amazon.com Inc.

Amazon.com Inc

Amazons weak, choppy trading is drawing attention ahead of earnings, with investors weighing AWS growth and AI demand against heavy infrastructure spending and pressure on cash flow. Bulls see AWS momentum and contracted demand as support for a rebound, while bears worry that rising capex may outpace returns.

Mastercard, Inc. is a technology company, which engages in the provision of payment solutions for the development and implementation of credit, debit, prepaid, commercial, and payment programs through its brands including Mastercard, Maestro, and Cirrus. It also offers cyber and intelligence solutions. The company was founded in November 1966 and is headquartered in Purchase, NY.

Mastercard Incorporated - Ordinary Shares - Class A

Mastercard Inc

Mastercard is drawing attention for a technical breakout to fresh highs, alongside Visa, after a strong run that traders say is holding above prior resistance. The reaction is broadly bullish, though some are watching for follow-through and questioning whether consumer spending and the stocks valuation can support the move.

Iovance Biotherapeutics, Inc. engages in the development and commercialization of cell therapies using autologous tumor-infiltrating lymphocytes (TIL) for the treatment of cancer. Its products include Amtagvi (lifileucel), and Proleukin (aldesleukin). The firm also develops investigational TIL therapies for other solid tumor cancers. The company was founded by Robert T. Brooke on September 17, 2007 and is headquartered in San Carlos, CA.

Iovance Biotherapeutics Inc

ESMO data on Iovances lifileucel program is driving attention, especially mature frontline melanoma results for lifileucel plus pembrolizumab that traders view as encouraging for the ongoing Phase 3 trial. The reaction is mixed: bulls emphasize response durability, while skeptics say the small melanoma cohort largely confirms earlier findings and the expanded sarcoma data look less compelling; some attribute the share-price weakness to a broader biotech selloff.

statis crypto Watchlist

Bitcoin

Ethereum

Solana

Ripple

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

A broad biotech selloff is driving attention, with traders pointing to rising-rate concerns, risk aversion and rotation away from smaller biotech stocks. The community is split between viewing the decline as an oversold buying opportunity and warning that weakness could continue, with technical support levels in focus.

SLS Stock Logs Worst Week In Over A Month: Retail Bulls Bet ASH Embargo Is Keeping Regal Results Under Wraps 

Equity

Sellas’s 600-square-foot ASH booth also fueled speculation about a potential clinical update.

Stocktwits Pharma Pulse: Moderna-Merck Cancer Vaccine Grabs Spotlight As Kidney-Cancer And MS Data Pour In 

Humacyte, Vera, Maze and Climb Bio will present dialysis-access and kidney-disease findings at ASN Kidney Week.

Stocktwits Biotech Dealmaker: Gilead, AstraZeneca And Roche Chase Pipeline Expansion Over Buyouts

Deals for AI discovery platforms and differentiated experimental candidates for obesity and solid tumors dominated the week.


Opus Genetics Secures FDA Approval For Eye Drops – Set To Receive Milestone Payment

The approval expands the therapy's use and triggers a milestone payment from commercial partner Viatris.

Omeros Faces Second Rejection Of Narsoplimab In Europe – OMER Stock Falls Below Key Support For First Time In Nearly 3 Months

European regulators rejected Omeros’ application for Narsoplimab, which is used to treat hematopoietic stem cell transplant-associated thrombotic microangiopathy.


IBRX Stock Eyes Weekly Slump Despite Anktiva FDA Win — Retail Stays Cautious Ahead Of Founder’s Trial Talk 

Founder Patrick Soon-Shiong has signaled a trial-status discussion at Friday’s Piper Sandler fireside chat.

IBRX Stock Rallies After FDA Clears Broader Anktiva Use In Bladder Cancer Months Ahead Of Deadline

FDA approved the drug Anktiva for adults with high-grade papillary-only non-muscle invasive bladder cancer that has not responded to a specific therapy called Bacillus Calmette-Guérin and has not invaded the bladder muscle.


Verastem Has Positive Early Cancer Data And $250M In New Funding: What VSTM Investors Need To Know 

Verastem reported positive results from its ongoing Phase 1/2 trial involving patients with advanced cancers carrying the KRAS G12D mutation.


SLS, IBRX Rise Premarket: Funds Raise Their Bets As J&J Stays ‘On The Lookout’ For Deals

J&J is open to strategic acquisitions and targets more than $50 billion in oncology sales by 2030.

BioNTech’s Cancer Drug Misses A Key Trial Goal – Citi Says Survival Data Could Preserve ‘A Meaningful Development Path’

BioNTech’s experimental cancer treatment combined with Merck’s Keytruda failed to significantly delay disease progression compared with Keytruda alone.


SPDR Series Trust - State Street SPDR S&P Biotech ETF

Neutral Sentiment

Up more than 1%

Flat to up 1%

Flat to down 1%

Down more than 1%

What do you think the S&amp;P 500&#39;s ($SPY) return will be next week?

Current Price	$144.32
Prev Close	$149.78
Open	$149.89
Dividend Yield	N/A
50-Day Moving Average	$157.96
Beta	N/A
Avg. Volume	8.47M
PE Ratio	N/A

52-Week High	$169.89
52-Week Low	$106.30
Market Capitalization	N/A
EPS (Annual)	N/A
Price to Book	N/A
Revenue Per Employee	N/A

Feed

News

Sentiment

Fundamentals

Info

XBI Fundamentals